Nicotinamide phosphoribosyltransferase

Nicotinamide phosphoribosyltransferase (NAmPRTase or NAMPT), formerly known as pre-B-cell colony-enhancing factor 1 (PBEF1) or visfatin for its extracellular form (eNAMPT),[5] is an enzyme that in humans is encoded by the NAMPT gene.[6] The intracellular form of this protein (iNAMPT) is the rate-limiting enzyme in the nicotinamide adenine dinucleotide (NAD+) salvage pathway that converts nicotinamide to nicotinamide mononucleotide (NMN) which is responsible for most of the NAD+ formation in mammals.[7] iNAMPT can also catalyze the synthesis of NMN from phosphoribosyl pyrophosphate (PRPP) when ATP is present.[8] eNAMPT has been reported to be a cytokine (PBEF) that promotes B cell maturation and inhibits neutrophil apoptosis.

NAMPT
Available structures PDB Ortholog search: PDBe RCSB List of PDB id codes 2E5B, 2E5C, 2E5D, 2GVG, 2GVJ, 3DGR, 3DHD, 3DHF, 3DKJ, 3DKL, 4JNM, 4JR5, 4KFN, 4KFO, 4KFP, 4L4L, 4L4M, 4LTS, 4LV9, 4LVA, 4LVB, 4LVD, 4LVF, 4LVG, 4LWW, 4M6P, 4M6Q, 4N9B, 4N9C, 4N9D, 4N9E, 4O0Z, 4O10, 4O12, 4O13, 4O14, 4O15, 4O16, 4O17, 4O18, 4O19, 4O1A, 4O1B, 4O1C, 4O1D, 4O28, 4WQ6
Identifiers
Aliases	NAMPT, 1110035O14Rik, PBEF, PBEF1, VF, VISFATIN, nicotinamide phosphoribosyltransferase
External IDs	OMIM: 608764 MGI: 1929865 HomoloGene: 4201 GeneCards: NAMPT
Gene location (Human) Chr. Chromosome 7 (human)[1] Band 7q22.3 Start 106,248,298 bp[1] End 106,286,326 bp[1]
Gene location (Mouse) Chr. Chromosome 12 (mouse)[2] Band 12|12 A3 Start 32,819,545 bp[2] End 32,853,349 bp[2]
RNA expression pattern More reference expression data
Gene ontology Molecular function • transferase activity • cytokine activity • protein homodimerization activity • transferase activity, transferring glycosyl groups • GO:0001948 protein binding • nicotinate-nucleotide diphosphorylase (carboxylating) activity • drug binding • nicotinamide phosphoribosyltransferase activity • identical protein binding • catalytic activity Cellular component • cytoplasm • cytosol • extracellular region • cell junction • extracellular exosome • cell nucleus • extracellular • nuclear speck • cell membrane Biological process • pyridine nucleotide biosynthetic process • insulin receptor signaling pathway • response to organic cyclic compound • NAD biosynthetic process • rhythmic process • female pregnancy • cell-cell signaling • positive regulation of nitric-oxide synthase biosynthetic process • circadian regulation of gene expression • circadian rhythm • positive regulation of cell proliferation • adipose tissue development • positive regulation of transcription from RNA polymerase II promoter • positive regulation of smooth muscle cell proliferation • signal transduction • NAD biosynthesis via nicotinamide riboside salvage pathway • regulation of receptor activity • microglial cell activation • aging • negative regulation of autophagy • regulation of lung blood pressure • neuron death • cellular response to ionizing radiation • cellular response to oxygen-glucose deprivation • cellular response to amyloid-beta • response to D-galactose • negative regulation of cellular senescence Sources:Amigo / QuickGO
Orthologs
Species	Human	Mouse
Entrez	10135	59027
Ensembl	ENSG00000105835	ENSMUSG00000020572
UniProt	P43490	Q99KQ4
RefSeq (mRNA)	NM_005746 NM_182790	NM_021524
RefSeq (protein)	NP_005737	NP_067499
Location (UCSC)	Chr 7: 106.25 – 106.29 Mb	Chr 12: 32.82 – 32.85 Mb
PubMed search	[3]	[4]
Wikidata
View/Edit Human View/Edit Mouse

nicotinamide phosphoribosyltransferase
Identifiers
EC number	2.4.2.12
CAS number	9030-27-7
Databases
IntEnz	IntEnz view
BRENDA	BRENDA entry
ExPASy	NiceZyme view
KEGG	KEGG entry
MetaCyc	metabolic pathway
PRIAM	profile
PDB structures	RCSB PDB PDBe PDBsum
Gene Ontology	AmiGO / QuickGO
Search PMC articles PubMed articles NCBI proteins

Reaction

iNAMPT catalyzes the following chemical reaction:

nicotinamide + 5-phosphoribosyl-1-pyrophosphate (PRPP) ${\displaystyle \rightleftharpoons }$ nicotinamide mononucleotide (NMN) + pyrophosphate (PPi)

Thus, the two substrates of this enzyme are nicotinamide and 5-phosphoribosyl-1-pyrophosphate (PRRP), whereas its two products are nicotinamide mononucleotide and pyrophosphate.[7]

This enzyme belongs to the family of glycosyltransferases, to be specific, the pentosyltransferases. This enzyme participates in nicotinate and nicotinamide metabolism.

Expression and regulation

The liver has the highest iNAMPT activity of any organ, about 10-20 times greater activity than kidney, spleen, heart, muscle, brain or lung.[9] iNAMPT is downregulated by an increase of miR-34a in obesity via a 3'UTR functional binding site of iNAMPT mRNA resulting in a reduction of NAD(+) and decreased SIRT1 activity.[10]

Endurance-trained athletes have twice the expression of iNAMPT in skeletal muscle compared with sedentary type 2 diabetic persons.[11] In a six-week study comparing legs trained by endurance exercise with untrained legs, iNAMPT was increased in the endurance-trained legs.[11] A study of 21 young (under 36) and 22 old (over 54) adults subject to 12 weeks of aerobic and resistance exercise showed aerobic exercise to increase skeletal muscle iNAMPT 12% and 28$% in young and old (respectively) and resistance exercise to increase skeletal muscle iNAMPT 25% and 30% in young and old (respectively).[12]

Aging, obesity, and chronic inflammation all reduce iNAMPT (and consequently NAD+) in multiple tissues.[13]

Function

iNAMPT catalyzes the condensation of nicotinamide (NAM) with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide (NMN), the first step in the biosynthesis of nicotinamide adenine dinucleotide (NAD+).[14] This salvage pathway, reusing NAM from enzymes using NAD+ (sirtuins, PARPs, CD38) and producing NAM as a waste product, is the major source of NAD+ production in the body.[14] De novo synthesis of NAD+ from tryptophan occurs only in the liver and kidney, overwhelmingly in the liver.[14]

Nomenclature

The systematic name of this enzyme class is nicotinamide-nucleotide:diphosphate phospho-alpha-D-ribosyltransferase. Other names in common use include:

• NMN pyrophosphorylase,
• nicotinamide mononucleotide pyrophosphorylase,
• nicotinamide mononucleotide synthetase, and
• NMN synthetase.

Extracellular NAMPT

Extracellular NAMPT (eNAMPT) is functionally different from intracellular NAMPT (iNAMPT), and less well understood (which is why the enzyme has been given so many names: NAMPT, PBEF and visfatin).[5] iNAMPT is secreted by many cell types (nobably adipocytes) to become eNAMPT. The sirtuin 1 (SIRT1) enzyme is required for eNAMPT secretion from adipose tissue.[15] eNAMPT may act more as a cytokine, although its receptor (possibly TLR4) has not been proven.[8] It has been demonstrated that eNAMPT could bind to and activate TLR4.[16]

eNAMPT can exist as a dimer or as a monomer, but is normally a circulating dimer.[15] As a monomer, eNAMPT has pro-inflammatory effects that are independent of NAD+, whereas the dimeric form of eNAMPT protects against these effects.[15]

eNAMPT/PBEF/visfatin was originally cloned as a putative cytokine shown to enhance the maturation of B cell precursors in the presence of Interleukin-7 (IL-7) and stem cell factor, it was therefore named "pre-B cell colony-enhancing factor" (PBEF).[6] When the gene encoding the bacterial nicotinamide phosphoribosyltransferase (nadV) was first isolated in Haemophilus ducreyi, it was found to exhibit significant homology to the mammalian PBEF gene.[17] Rongvaux et al.[18] demonstrated genetically that the mouse PBEF gene conferred Nampt enzymatic activity and NAD-independent growth to bacteria lacking nadV. Revollo et al.[19] determined biochemically that the mouse PBEF gene product encodes an eNAMPT enzyme, capable of modulating intracellular NAD levels. Others have since confirmed these findings.[20] More recently, several groups have reported the crystal structure of Nampt/PBEF/visfatin and they all show that this protein is a dimeric type II phosphoribosyltransferase enzyme involved in NAD biosynthesis.[21][22][23]

eNAMPT has been shown to be more enzymatically active than iNAMPT, supporting the proposal that eNAMPT from adipose tissue enhances NAD+ in tissues with low levels of iNAMPT, notably pancreatic beta cells and brain neurons.[24]

Hormone claim retracted

Although the original cytokine function of PBEF has not been confirmed to date, others have since reported or suggested a cytokine-like function for this protein.[25] In particular, Nampt/PBEF was recently re-identified as a "new visceral fat-derived hormone" named visfatin.[26] It is reported that visfatin is enriched in the visceral fat of both humans and mice and that its plasma levels increase during the development of obesity.[26] Noteworthy is that visfatin is reported to exert insulin-mimetic effects in cultured cells and to lower plasma glucose levels in mice by binding to and activating the insulin receptor.[26] However, the physiological relevance of visfatin is still in question because its plasma concentration is 40 to 100-fold lower than that of insulin despite having similar receptor-binding affinity.[26][27][28] In addition, the ability of visfatin to bind and activate the insulin-receptor has yet to be confirmed by other groups.

On 26 October 2007, A. Fukuhara (first author), I.Shimomura (senior author) and the other co-authors of the paper,[26] who first described Visfatin as a visceral-fat derived hormone that acts by binding and activating the insulin receptor, retracted the entire paper[26] at the suggestion of the editor of the journal 'Science' and recommendation of the Faculty Council of Osaka University Medical School after a report of the Committee for Research Integrity.[29]

As a drug target

Because cancer cells utilize increased glycolysis, and because NAD enhances glycolysis, iNAMPT is often amplified in cancer cells.[30][31] APO866 is an experimental drug that inhibits this enzyme.[32] It is being tested for treatment of advanced melanoma, cutaneous T-cell lymphoma (CTL), and refractory or relapsed B-chronic lymphocytic leukemia.

Anti-aging biomedical company Calico has licensed the experimental P7C3 analogs involved in enhancing iNAMPT activity.[33] P7C3 compounds have been shown in a number of publications to be beneficial in animal models for age-related neurodegeneration.[34][35]

References

1. GRCh38: Ensembl release 89: ENSG00000105835 - Ensembl, May 2017
2. GRCm38: Ensembl release 89: ENSMUSG00000020572 - Ensembl, May 2017
3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
5. Grolla AA, Travelli C, Genazzani AA, Sethi JK (2016). "Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine". British Journal of Pharmacology. 173 (14): 2182–2194. doi:10.1111/bph.13505. PMC 4919578. PMID 27128025.
6. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I (February 1994). "Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor". Molecular and Cellular Biology. 14 (2): 1431–7. doi:10.1128/MCB.14.2.1431. PMC 358498. PMID 8289818.
7. Revollo JR, Grimm AA, Imai S (March 2007). "The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals". Current Opinion in Gastroenterology. 23 (2): 164–70. doi:10.1097/MOG.0b013e32801b3c8f. PMID 17268245. S2CID 31308112.
8. Galli U, Colombo G, Travelli C, Grolla AA (2020). "Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy". Frontiers in Pharmacology. 11: 656. doi:10.3389/fphar.2020.00656. PMC 7235340. PMID 32477131.
9. Hwang ES, Song SB (2017). "Nicotinamide is an inhibitor of SIRT1 in vitro, but can be a stimulator in cells". Cellular and Molecular Life Sciences. 74 (18): 3347–3362. doi:10.1007/s00018-017-2527-8. PMID 28417163. S2CID 25896400.
10. Choi SE, Fu T, Seok S, Kim DH, Yu E, Lee KW, Kang Y, Li X, Kemper B, Kemper JK (December 2013). "Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT". Aging Cell. 12 (6): 1062–72. doi:10.1111/acel.12135. PMC 3838500. PMID 23834033.
11. Jadeja RN, Thounaojam MC, Martin PM (2020). "Implications of NAD + Metabolism in the Aging Retina and Retinal Degeneration". Oxidative Medicine and Cellular Longevity. 2020: 2692794. doi:10.1155/2020/2692794. PMC 7238357. PMID 32454935.
12. de Guia RM, Agerholm M, Nielsen TS, Treebak JT (2019). "Aerobic and resistance exercise training reverses age-dependent decline in NAD + salvage capacity in human skeletal muscle". Physiological Reports. 7 (12): e14139. doi:10.14814/phy2.14139. PMC 6577427. PMID 31207144.
13. Poljsak B (2089). "NAMPT-Mediated NAD Biosynthesis as the Internal Timing Mechanism: In NAD+ World, Time Is Running in Its Own Way". Rejuvenation Research. 21 (3): 210–224. doi:10.1089/rej.2017.1975. PMID 28756747. Check date values in: |date= (help)
14. Liu L, Su X, Quinn WJ, Rabinowitz JD (2018). "Quantitative Analysis of NAD Synthesis-Breakdown Fluxes". Cell Metabolism. 27 (5): 1067–1080. doi:10.1016/j.cmet.2018.03.018. PMC 5932087. PMID 29685734.
15. Yoshino J, Baur JA, Imai S (2018). "NAD + Intermediates: The Biology and Therapeutic Potential of NMN and NR". Cell Metabolism. 27 (3): 513–528. doi:10.1016/j.cmet.2017.11.002. PMC 5842119. PMID 29249689.
16. Garcia, Joe G. N.; Liang, Jie; Wang, Ting; Yousef, Mohammed; Saadat, Laleh; Letsiou, Eleftheria; Sammani, Saad; Quijada, Hector; Siddiqui, Shahid S. (14 August 2015). "Unique Toll-Like Receptor 4 Activation by NAMPT/PBEF Induces NFκB Signaling and Inflammatory Lung Injury". Scientific Reports. 5: 13135. Bibcode:2015NatSR...513135C. doi:10.1038/srep13135. ISSN 2045-2322. PMC 4536637. PMID 26272519.
17. Martin PR, Shea RJ, Mulks MH (February 2001). "Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence". Journal of Bacteriology. 183 (4): 1168–74. doi:10.1128/JB.183.4.1168-1174.2001. PMC 94989. PMID 11157928.
18. Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, Andris F (November 2002). "Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis". European Journal of Immunology. 32 (11): 3225–34. doi:10.1002/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L. PMID 12555668.
19. Revollo JR, Grimm AA, Imai S (December 2004). "The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells". The Journal of Biological Chemistry. 279 (49): 50754–63. doi:10.1074/jbc.M408388200. PMID 15381699.
20. van der Veer E, Nong Z, O'Neil C, Urquhart B, Freeman D, Pickering JG (July 2005). "Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation". Circulation Research. 97 (1): 25–34. doi:10.1161/01.RES.0000173298.38808.27. PMID 15947248.
21. Wang T, Zhang X, Bheda P, Revollo JR, Imai S, Wolberger C (July 2006). "Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme". Nature Structural & Molecular Biology. 13 (7): 661–2. doi:10.1038/nsmb1114. PMID 16783373. S2CID 28674013.
22. Kim MK, Lee JH, Kim H, Park SJ, Kim SH, Kang GB, Lee YS, Kim JB, Kim KK, Suh SW, Eom SH (September 2006). "Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866". Journal of Molecular Biology. 362 (1): 66–77. doi:10.1016/j.jmb.2006.06.082. PMID 16901503.
23. Khan JA, Tao X, Tong L (July 2006). "Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents". Nature Structural & Molecular Biology. 13 (7): 582–8. doi:10.1038/nsmb1105. PMID 16783377. S2CID 13305867.
24. Imai S (2016). "The NAD World 2.0: the importance of the inter-tissue communication mediated by NAMPT/NAD +/SIRT1 in mammalian aging and longevity control". npj Systems Biology and Applications. 2: 16018. doi:10.1038/npjsba.2016.18. PMC 5516857. PMID 28725474.
25. Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, Marshall JC (May 2004). "Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis". The Journal of Clinical Investigation. 113 (9): 1318–27. doi:10.1172/JCI19930. PMC 398427. PMID 15124023.
26. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I (January 2005). "Visfatin: a protein secreted by visceral fat that mimics the effects of insulin". Science. 307 (5708): 426–30. Bibcode:2005Sci...307..426F. doi:10.1126/science.1097243. PMID 15604363. S2CID 86231101. (Retracted, see PMID 17962537)
27. Stephens JM, Vidal-Puig AJ (April 2006). "An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity". Current Opinion in Lipidology. 17 (2): 128–31. doi:10.1097/01.mol.0000217893.77746.4b. PMID 16531748. S2CID 46178743.
28. Arner P (January 2006). "Visfatin--a true or false trail to type 2 diabetes mellitus". The Journal of Clinical Endocrinology and Metabolism. 91 (1): 28–30. doi:10.1210/jc.2005-2391. PMID 16401830.
29. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I (October 2007). "Retraction". Science. 318 (5850): 565.2–565. doi:10.1126/science.318.5850.565b. PMID 17962537. S2CID 220091956.
30. Yaku K, Okabe K, Hikosaka K, Nakagawa T (2018). "NAD Metabolism in Cancer Therapeutics". Frontiers in Oncology. 8: 622. doi:10.3389/fonc.2018.00622. PMC 6315198. PMID 30631755.
31. Pramono AA, Rather GM, Herman H (2020). "NAD- and NADPH-Contributing Enzymes as Therapeutic Targets in Cancer: An Overview". Biomolecules. 10 (3): 358. doi:10.3390/biom10030358. PMC 7175141. PMID 32111066.
32. APO866 Not Effective for Cutaneous T-Cell Lymphoma. March 2016
33. "UT Southwestern researchers discover novel class of NAMPT activators for neurodegenerative disease; Calico enters into exclusive collaboration with 2M to develop UTSW technology".
34. Cain, Chris (2014). "NAMPT neuroprotection". Science-Business EXchange. 7 (38): 1112. doi:10.1038/scibx.2014.1112.
35. Wang G, Han T, Nijhawan D, Theodoropoulos P, Naidoo J, Yadavalli S, Mirzaei H, Pieper AA, Ready JM, McKnight SL (September 2014). "P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage". Cell. 158 (6): 1324–1334. doi:10.1016/j.cell.2014.07.040. PMC 4163014. PMID 25215490.

Further reading

• Preiss J, Handler P (1957). "Enzymatic synthesis of nicotinamide mononucleotide". J. Biol. Chem. 225 (2): 759–770. PMID 13416279.
• Stephens JM, Vidal-Puig AJ (April 2006). "An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity". Current Opinion in Lipidology. 17 (2): 128–31. doi:10.1097/01.mol.0000217893.77746.4b. PMID 16531748. S2CID 46178743.
• Bełtowski J (June 2006). "Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity?". Medical Science Monitor. 12 (6): RA112–9. PMID 16733497.
• Pilz S, Mangge H, Obermayer-Pietsch B, März W (February 2007). "Visfatin/pre-B-cell colony-enhancing factor: a protein with various suggested functions". Journal of Endocrinological Investigation. 30 (2): 138–44. doi:10.1007/bf03347412. PMID 17392604. S2CID 20329604.
• Siderovski DP, Blum S, Forsdyke RE, Forsdyke DR (October 1990). "A set of human putative lymphocyte G0/G1 switch genes includes genes homologous to rodent cytokine and zinc finger protein-encoding genes". DNA and Cell Biology. 9 (8): 579–87. doi:10.1089/dna.1990.9.579. PMID 1702972.
• Sanger Centre, The; Washington University Genome Sequencing Cente, The (November 1998). "Toward a complete human genome sequence". Genome Research. 8 (11): 1097–108. doi:10.1101/gr.8.11.1097. PMID 9847074.
• Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, Andris F (November 2002). "Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis". European Journal of Immunology. 32 (11): 3225–34. doi:10.1002/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L. PMID 12555668.
• Kitani T, Okuno S, Fujisawa H (June 2003). "Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor". FEBS Letters. 544 (1–3): 74–8. doi:10.1016/S0014-5793(03)00476-9. PMID 12782293. S2CID 8442143.
• Reuter TY, Medhurst AL, Waisfisz Q, Zhi Y, Herterich S, Hoehn H, Gross HJ, Joenje H, Hoatlin ME, Mathew CG, Huber PA (October 2003). "Yeast two-hybrid screens imply involvement of Fanconi anemia proteins in transcription regulation, cell signaling, oxidative metabolism, and cellular transport". Experimental Cell Research. 289 (2): 211–21. doi:10.1016/S0014-4827(03)00261-1. PMID 14499622.
• Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, Marshall JC (May 2004). "Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis". The Journal of Clinical Investigation. 113 (9): 1318–27. doi:10.1172/JCI19930. PMC 398427. PMID 15124023.
• Rush J, Moritz A, Lee KA, Guo A, Goss VL, Spek EJ, Zhang H, Zha XM, Polakiewicz RD, Comb MJ (January 2005). "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells". Nature Biotechnology. 23 (1): 94–101. doi:10.1038/nbt1046. PMID 15592455. S2CID 7200157.
• Janssen JJ, Klaver SM, Waisfisz Q, Pasterkamp G, de Kleijn DP, Schuurhuis GJ, Ossenkoppele GJ (June 2005). "Identification of genes potentially involved in disease transformation of CML". Leukemia. 19 (6): 998–1004. doi:10.1038/sj.leu.2403735. PMID 15815727.
• van der Veer E, Nong Z, O'Neil C, Urquhart B, Freeman D, Pickering JG (July 2005). "Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation". Circulation Research. 97 (1): 25–34. doi:10.1161/01.RES.0000173298.38808.27. PMID 15947248.
• Ognjanovic S, Ku TL, Bryant-Greenwood GD (July 2005). "Pre-B-cell colony-enhancing factor is a secreted cytokine-like protein from the human amniotic epithelium". American Journal of Obstetrics and Gynecology. 193 (1): 273–82. doi:10.1016/j.ajog.2004.11.003. PMC 1382169. PMID 16021090.

External links

• visfatin,+human at the US National Library of Medicine Medical Subject Headings (MeSH)
• NAMPT human gene location in the UCSC Genome Browser.
• NAMPT human gene details in the UCSC Genome Browser.
• Overview of all the structural information available in the PDB for UniProt: P43490 (Human Nicotinamide phosphoribosyltransferase) at the PDBe-KB.
• Overview of all the structural information available in the PDB for UniProt: Q99KQ4 (Mouse Nicotinamide phosphoribosyltransferase) at the PDBe-KB.